首页> 外国专利> Pharmaceutical composition for treating acute myeloid leukemia or myelodysplastic syndrome or composition for predicting the relapse risk of acute myeloid leukemia or myelodysplastic syndrome

Pharmaceutical composition for treating acute myeloid leukemia or myelodysplastic syndrome or composition for predicting the relapse risk of acute myeloid leukemia or myelodysplastic syndrome

机译：用于治疗急性髓性白血病或骨髓增生异常综合症的药物组合物或用于预测急性髓性白血病或骨髓增生异常综合症的复发风险的组合物

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a pharmaceutical composition for treating acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), and a composition for predicting a risk of relapse of acute myeloid leukemia or myelodysplastic syndrome. The pharmaceutical composition has an excellent effect of treating acute myeloid leukemia or myelodysplastic syndrome. In addition, the pharmaceutical composition can be used advantageously for preventing a relapse of acute myeloid leukemia or myelodysplastic syndrome. Further, the composition can be used efficiently for prognosing acute myeloid leukemia or myelodysplastic syndrome of a subject, or for simply diagnosing a risk of relapse of acute myeloid leukemia or myelodysplastic syndrome.

机译：本发明涉及用于治疗急性髓细胞性白血病（AML）或骨髓增生异常综合症（MDS）的药物组合物，以及用于预测急性髓细胞性白血病或骨髓增生异常综合症复发的风险的组合物。该药物组合物具有治疗急性髓细胞性白血病或骨髓增生异常综合症的优异效果。另外，该药物组合物可有利地用于预防急性髓细胞性白血病或骨髓增生异常综合症的复发。此外，该组合物可有效地用于预后受试者的急性髓细胞性白血病或骨髓增生异常综合症，或仅用于诊断急性髓细胞性白血病或骨髓增生异常综合症复发的风险。

著录项

公开/公告号KR20200063081A

专利类型
公开/公告日2020-06-04

原文格式PDF
申请/专利权人 THE ASAN FOUNDATION;KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION;
展开▼

申请/专利号KR20190153671
发明设计人 LEE KYOO HYUNG;KIM HUN SIK;CHOI EUN JI;LEE HYEON HO;IN PYO CHOI;SUK RAN YOON;KIM HANNA;JEONG SOL GI;PARK SOOYEON;
展开▼

申请日2019-11-26
分类号A61K35/17;A61P35/02;C12N5/0783;C12Q1/6886;
国家 KR
入库时间 2022-08-21 11:06:50

相似文献

专利
外文文献
中文文献